Clinical Trial Update: Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin [Phase 4]

View source ↗

Summary

Phase 4 trial comparing insulin glargine (rDNA origin) injection to pioglitazone as add-on therapy in type 2 diabetes patients not adequately controlled on sulf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED